Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mitchell R Smith

Showing results (91-100 of 129) with videos related to

Pageof 13
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 2, 2012
Phase II study of rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone immunochemotherapy followed by yttrium-90-ibritumomab tiuxetan in untreated mantle-cell lymphoma: Eastern Cooperative Oncology Group Study E1499Mitchell R Smith, Hailun Li, Leo Gordon, et al.
Blood|January 25, 2014
Phase 2 study of VcR-CVAD with maintenance rituximab for untreated mantle cell lymphoma: an Eastern Cooperative Oncology Group study (E1405)Julie E Chang, Hailun Li, Mitchell R Smith, et al.
Molecular Cancer|November 6, 2015
miR-377-dependent BCL-xL regulation drives chemotherapeutic resistance in B-cell lymphoid malignanciesSayer Al-Harbi, Gaurav S Choudhary, Jey Sabith Ebron, et al.
Oncotarget|August 29, 2015
A synthetic peptide targeting the BH4 domain of Bcl-2 induces apoptosis in multiple myeloma and follicular lymphoma cells alone or in combination with agents targeting the BH3-binding pocket of Bcl-2Andrew R Lavik, Fei Zhong, Ming-Jin Chang, et al.
Oncoimmunology|August 17, 2017
NK cell dysfunction in chronic lymphocytic leukemia is associated with loss of the mature cells expressing inhibitory killer cell Ig-like receptorsAlexander W MacFarlane, Mowafaq Jillab, Mitchell R Smith, et al.
Haematologica|December 14, 2004
Phase II study of fludarabine and alpha-interferon in patients with low-grade non-Hodgkin's lymphomaGloria J Morris, Michael M Millenson, Kristin Padavic-Shaller, et al.
British Journal of Haematology|April 10, 2014
Comparison of the prognostic utility of the revised International Prognostic Scoring System and the French Prognostic Scoring System in azacitidine-treated patients with myelodysplastic syndromesAmer M Zeidan, Ju-Whei Lee, Thomas Prebet, et al.
British Journal of Haematology|July 14, 2016
Early stage, bulky Hodgkin lymphoma patients have a favorable outcome when treated with or without consolidative radiotherapy: potential role of PET scan in treatment planningVan T Nguyen, Priyanka A Pophali, Judy P Tsai, et al.
Blood|August 11, 2017
A multi-institutional outcomes analysis of patients with relapsed or refractory DLBCL treated with ibrutinibAllison M Winter, Daniel J Landsburg, Anthony R Mato, et al.
PET Clinics|June 28, 2012
Prediction and Early Detection of Response by NMR Spectroscopy and ImagingSeung-Cheol Lee, Fernando Arias-Mendoza, Harish Poptani, et al.
Pageof 13

Showing results (91-100 of 129) with videos related to

Sort By:
Pageof 13
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 2, 2012
Phase II study of rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone immunochemotherapy followed by yttrium-90-ibritumomab tiuxetan in untreated mantle-cell lymphoma: Eastern Cooperative Oncology Group Study E1499Mitchell R Smith, Hailun Li, Leo Gordon, et al.
Blood|January 25, 2014
Phase 2 study of VcR-CVAD with maintenance rituximab for untreated mantle cell lymphoma: an Eastern Cooperative Oncology Group study (E1405)Julie E Chang, Hailun Li, Mitchell R Smith, et al.
Molecular Cancer|November 6, 2015
miR-377-dependent BCL-xL regulation drives chemotherapeutic resistance in B-cell lymphoid malignanciesSayer Al-Harbi, Gaurav S Choudhary, Jey Sabith Ebron, et al.
Oncotarget|August 29, 2015
A synthetic peptide targeting the BH4 domain of Bcl-2 induces apoptosis in multiple myeloma and follicular lymphoma cells alone or in combination with agents targeting the BH3-binding pocket of Bcl-2Andrew R Lavik, Fei Zhong, Ming-Jin Chang, et al.
Oncoimmunology|August 17, 2017
NK cell dysfunction in chronic lymphocytic leukemia is associated with loss of the mature cells expressing inhibitory killer cell Ig-like receptorsAlexander W MacFarlane, Mowafaq Jillab, Mitchell R Smith, et al.
Haematologica|December 14, 2004
Phase II study of fludarabine and alpha-interferon in patients with low-grade non-Hodgkin's lymphomaGloria J Morris, Michael M Millenson, Kristin Padavic-Shaller, et al.
British Journal of Haematology|April 10, 2014
Comparison of the prognostic utility of the revised International Prognostic Scoring System and the French Prognostic Scoring System in azacitidine-treated patients with myelodysplastic syndromesAmer M Zeidan, Ju-Whei Lee, Thomas Prebet, et al.
British Journal of Haematology|July 14, 2016
Early stage, bulky Hodgkin lymphoma patients have a favorable outcome when treated with or without consolidative radiotherapy: potential role of PET scan in treatment planningVan T Nguyen, Priyanka A Pophali, Judy P Tsai, et al.
Blood|August 11, 2017
A multi-institutional outcomes analysis of patients with relapsed or refractory DLBCL treated with ibrutinibAllison M Winter, Daniel J Landsburg, Anthony R Mato, et al.
PET Clinics|June 28, 2012
Prediction and Early Detection of Response by NMR Spectroscopy and ImagingSeung-Cheol Lee, Fernando Arias-Mendoza, Harish Poptani, et al.
Pageof 13